Sandy Srinivas
@sandysrimd
Followers
1K
Following
2K
Media
81
Statuses
2K
I am a medical oncologist with clinical and research interest in urologic cancers
Joined May 2015
Clinical and #Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive #ProstateCancer @EUplatinum
#PSMA
https://t.co/ABni4kCsHl
0
1
6
Biochemical recurrence isn’t just relapse! Next-gen imaging like PSMA PET now reveals “PSMA+BCR,” a hidden state between local and metastatic disease. The NCI Working Group urges trials to rethink control arms, endpoints, and toxicity, less intensity, more precision. @theNCI
0
4
6
Impact of Systemic Therapy for Renal Cell Carcinoma With a Tumor Thrombus: Results From the Intercontinental Collaboration on Renal Cell Carcinoma Database - Clinical Genitourinary Cancer
clinical-genitourinary-cancer.com
MicroabstractThe role of systemic therapy in the management of these renal cell carcinoma with a tumor thrombus (RCCC-TT) patients is poorly understood. In this multi-institutional analysis, we study...
0
5
18
Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews
#ESMO25 #ESMOAmbassadors @OncoAlert
3
16
39
RAMPART #ESMO25 adjuvant durvalumab/tremelimumab delays DFS in adjuvant RCC vs supportive care. This is confusing as ipi/nivo did not hit DFS. Durvalumab monotherapy data will help on component parts. Benefit seems confined to good risk. Adjuvant pembro has OS here. @OncoAlert
1
22
52
The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
4
51
111
ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity @JoshMeeks
2
77
176
🚨 #ESMO25 Update! 5-year follow-up from CheckMate-274 shows durable benefit of adjuvant nivolumab in high-risk muscle-invasive bladder cancer 💪 🔹 DFS: 26 vs 9 mo → HR 0.66 🔹 OS: 75 vs 51 mo (nivo vs placebo) 🔹 Benefit maintained even after neoadjuvant chemo 🔹 ctDNA
0
10
18
Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)
3
46
112
2420MO – STOPCAP Meta-analysis #ESMO25 📊 Pooled IPD from PEACE-1 & STAMPEDE: prostate RT in synchronous mHSPC. ⚖️ No overall OS benefit (HR 0.93, p=0.11) ✅ Low-volume benefit: HR 0.79 → +7.7% 5-yr OS ✅ ≤4 bone mets: HR 0.84 (+4.9%) ➡️ Benefit confined to low-volume,
0
60
126
Congrats to #ASTRO25 Gold Medal recipients — @Qle_stanford personal story esp compelling as refugee immigrant to chair @StanfordRadOnc and @NRGonc group co-chair. She, @d__beyer #LarryMarks #JatinderPalta have contributed significantly through their careers. 👏👏👏
1
2
17
Special year for @StanfordRadOnc ! @Qle_stanford awarded Gold Medal🏅 Kate Horst and @ElizabethAKidd awarded FASTRO recognition. Iris Gibbs awarded mentorship award. Congratulations👏 and thank you for all your mentorship !#ASTRO25 @OncoAlert
2
3
24
🧬 Determinants of Late Metastases in Renal Cell Carcinoma 📌 Recent evidence shows that late-metastatic RCC represents a biologically distinct subset, often associated with lower grade, reduced necrosis, and a less aggressive clinical course compared to early metastases. 🧩
0
2
13
🧪 A step forward in bladder-sparing strategies for MIBC. An international consensus defines clinical complete response (cCR) and proposes event-free survival (EFS) as the preferred endpoint in next-gen perioperative trials. #BladderCancer @OncoAlert @JCO_ASCO
2
26
54
🔔 Testicular cancer is the most common solid tumor in people with testicles aged 15–44. A @TheLancet seminar reviews management of seminoma and non-seminoma, follow-up, relapse strategies, and future directions. DOI 👉🏻 https://t.co/6ksIRTZmCf
#CánCare #oncology
4
67
186
This is huge. Congrats to @tompowles1 @BartsECMC & team who took this from a brilliant paper in @Nature in 2021 to a paradigm-shifting + P3 trial. @BladderCancerUS @IBCG_BladderCA
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche
https://t.co/OlOirNfWHo
4
31
89
Congrats to all who made this possible. This trial showed 53% pCR and 64% 2‑yr EFS with neoadjuvant chemo‑immunotherapy in non-urothelial MIBC subtypes. Time for collaboration and more studies in this neglected population. @RubenRaychaud @arkhaki @spsutkaMD @PGrivasMDPhD
2
34
111
Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review - European Urology Focus
0
12
34